Q-omics provides the consensus-scored WDR13 profile across patient tissues and cancer cell-line models. WDR13 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, WDR13 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, WDR13 protein abundance shows 24,892 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCEC, KIRC, and PDAC as cancer lineages where WDR13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR13 survival associations across molecular data types. WDR13 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR13 RNA expression–survival associations across cancer types. High WDR13 expression shows unfavorable associations in KICH, UVM and LIHC, but favorable associations in UCEC, KIRP and OV. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCEC as the clearest survival context for WDR13 RNA expression.
This table summarizes WDR13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WDR13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR13 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, COAD, LIHC and KIRP. The KIRC box plot shows higher WDR13 RNA expression in tumor versus normal tissue (log2 FC = +1.060, t-test p < 0.001).
This table shows molecular features associated with WDR13 in patient tissues and cancer cell lines. In patient samples, WDR13 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
